✦ LIBER ✦

PCN96 CANCER PATIENT PREFERENCES AND WILLINGNESS TO PAY FOR PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN THE UNITED STATES

✍ Scribed by P.J. Miller; S. Balu; D. Buchner; M.S. Walker; E.J. Stepanski; L.S. Schwartzberg

Book ID: 119309707
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 57 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.02.951

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN44 Examining the Cost of Chemotherapy

PCN44 Examining the Cost of Chemotherapy Induced Nausea and Vomiting in Patients Treated for Cancer in a Medicaid Population

✍ Knoth, R.L.; Faria, C.; Li, X.; Powers, A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Guideline for the prevention and treatme

Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients

✍ Dupuis, L. Lee; Robinson, Paula D.; Boodhan, Sabrina; Holdsworth, Mark; Portwine 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

PCN95 The Cost-Effectiveness of Aprepita

PCN95 The Cost-Effectiveness of Aprepitant for the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy in Breast Cancer Patients Compared to Current Clinical Practice in Scotland

✍ Nikoglou, E.; Humphreys, S.; Pellissier, J.; O' Regan, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

9048 Aprepitant for the prevention of ch

9048 Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer

✍ Rapoport, B.; Boice, J.A.; Brown, C.; Street, J.C.; Hardwick, J.S.; Carides, A.D 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Results of an Open-Label Study to Evalua

Results of an Open-Label Study to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Carboplatin-Containing Chemotherapy in Patients with Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Carcinoma (Stage I-IV) or Papillary Serous Cancer of the Uterus

✍ Patrick Timmins III; Daniel Kredentser; Kenneth Hancock; Mark Messing; Kristi A. 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 104 KB